Reply to MR Romano et al.
Smith
J
J
Steel
D
D
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000601:surgery; D006801:Humans; D058449:Intravitreal Injections; D019106:Postoperative Hemorrhage / Q000517:prevention & control*; D011300:Preoperative Care; D014821:Vitrectomy / Q000379:methods*; D014823:Vitreous Hemorrhage / Q000517:prevention & control*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab